Journal: Cell Reports Medicine

Article Title: Neoadjuvant Fc-enhanced anti-CTLA-4 targets Tregs to augment androgen deprivation in high-risk prostate cancer: A randomized phase I trial

doi: 10.1016/j.xcrm.2026.102638

Figure Lengend Snippet: Phenotypic modulation of T cells and enhanced priming by anti-CTLA4-NF (A) PaCMAP plot of NeoRED-P patient tumor-infiltrating CD8 T cells by CyTOF. Clusters were derived from FlowSOM. (B) Pseudocolor density plots of CD8 T cells in PaCMAP space stratified by treatment group. (C) Expression of CD39 and 4-1BB by geometric MI on CD8 T cells as represented by color mapping on PaCMAP plot. (D) Violin plot representing frequency of manually gated CD39 + 4-1BB + CD8 T cells as a percentage of all CD8 T cells stratified by treatment group. Untreated, n = 7; ADT, n = 8; ADT + anti-CTLA4-NF, n = 8. Single patient with MSI hi status called out in plot. For this and all violin plots to follow, solid lines denote group medians, while dashed lines denote quartiles. (E) PaCMAP plot of NeoRED-P patient tumor-infiltrating CD4 + FoxP3 - Tconv cells by CyTOF. Clusters were derived from FlowSOM. (F) Pseudocolor density plots of CD4 Tconv cells in PaCMAP space stratified by treatment group. (G) Expression of CD39 and 4-1BB by geometric MI on CD4 Tconv as represented by color mapping on PaCMAP plot. (H) Violin plot representing frequency of manually gated CD39 + 4-1BB + CD4 Tconv cells as a percentage of all CD8 T cells stratified by treatment group. Untreated, n = 7; ADT, n = 8; ADT + anti-CTLA4-NF, n = 8. Single patient with MSI hi status called out in plot. (I) PaCMAP plot of MycCaP-infiltrating CD8 T cells by 45-parameter flow cytometry in response to ADT, ADT + anti-CTLA4 (ND), or ADT + anti-CTLA4 (D). Clusters were derived from FlowSOM. (J) Pseudocolor density plots of CD8 T cells in PaCMAP space stratified by treatment group. (K) Expression of CD39 and 4-1BB by geometric MFI on CD8 T cells as represented by color mapping on PaCMAP plot. (L) Violin plot representing frequency of manually gated CD39 + 4-1BB + CD8 T cells as a percentage of all CD8 T cells stratified by treatment group. (M) Biaxial plots representing expression of CD44 and Ki67 on CD8 T cells in tumor-draining lymph nodes of mice shown in (I–L). (N) Biaxial plots representing expression of CD44 and Ki67 on CD4 + FoxP3 − Tconv cells in tumor-draining lymph nodes of mice shown in (L–O). (O) Violin plots representing frequencies of CD44 + Ki67 + CD8 and CD4 Tconv cells as a percentage of parent populations stratified by treatment group. Two-tailed Welch’s t test was used to assess statistical significance. All murine data shown are n = 7 per group and representative of two independent experiments each for survival and immune profiling studies.

Article Snippet: Anti-Human CD39 (A1) 160Gd , Standard BioTools , Cat# 3160004B.

Techniques: Derivative Assay, Expressing, Flow Cytometry, Two Tailed Test

Journal: Frontiers in Immunology

Article Title: Targeting CD39 in combination with IL-2/anti-IL-2 complexes enhances cytotoxic immunity and limits tumor progression

doi: 10.3389/fimmu.2026.1730342

Figure Lengend Snippet: Pharmacological inhibition of CD39 combined with IL-2cx enhances antitumor CD8 + T cell response. WT mice were injected s.c. with B16F10-OVA cells and treated with PBS (gray), POM-1 (red), IL-2/anti-IL-2 complex (IL-2cx, green), or the combination POM-1+ IL-2cx (blue). (A) Schematic representation of treatment protocol. (B) Tumor volumes measured on 7-15 d.p.i. Statistical analysis was performed on day 15 d.p.i. (C) Frequencies of T-I CD45 + leukocytes. (D) Frequencies of T-I CD8 + T cells. (E) Frequencies of T-I Ki-67 + CD8 + T cells. (F) Frequencies of T-I OVA-specific CD8 + T cells. (G) Representative contour plots and frequencies of GzmB + , CD107a + , Perforin +, or IFN-γ + total T-I CD8 + T cells. All data were collected on day 15 p.i. Results are representative of 4 independent experiments. Data are presented as mean ± SD. Statistical analysis was performed using one-way ANOVA with multiple comparisons. Non-significant differences are not shown; * P ≤ 0.05; ** P ≤ 0.01; *** P ≤ 0.001; **** P ≤ 0.0001.

Article Snippet: The CD39 inhibitor POM-1 (TOCRIS) was injected i.p. in 200 μL PBS containing 250 μg of POM-1 on days 5, 7, 10, and 13 p.i.

Techniques: Inhibition, Injection

Journal: Frontiers in Immunology

Article Title: Targeting CD39 in combination with IL-2/anti-IL-2 complexes enhances cytotoxic immunity and limits tumor progression

doi: 10.3389/fimmu.2026.1730342

Figure Lengend Snippet: Treatment with POM-1 plus IL-2cx increased the frequency of PD-1 Int CD8 + T cells with cytotoxic potential. WT mice were injected s.c. with B16F10-OVA cells and treated with PBS (gray), POM-1 (red), IL-2/anti-IL-2 complex (IL-2cx, green), or the combination POM-1 + IL-2cx (blue). (A) Frequencies of PD-1 Neg , PD-1 Int , and PD-1 High total T-I CD8 + T cells. (B) Frequencies of TOX- expressing (left) and TCF-1 + expressing (right) PD-1 Int total T-I CD8 + T cells. (C) Frequencies of Ki-67 + expressing PD-1 Int total T-I CD8 + T cells. (D) GzmB + , Perforin + , CD107a + , or IFN-γ + PD-1 Int total T-I CD8 + T cells. All data were collected on day 15 p.i. Data are presented as mean ± SD. Results are representative of 4 independent experiments. Statistical analysis was performed using one-way ANOVA with multiple comparisons. Non-significant differences are not shown; * P ≤ 0.05; ** P ≤ 0.01; *** P ≤ 0.001; **** P ≤ 0.0001.

Article Snippet: The CD39 inhibitor POM-1 (TOCRIS) was injected i.p. in 200 μL PBS containing 250 μg of POM-1 on days 5, 7, 10, and 13 p.i.

Techniques: Injection, Expressing

Journal: Frontiers in Immunology

Article Title: Targeting CD39 in combination with IL-2/anti-IL-2 complexes enhances cytotoxic immunity and limits tumor progression

doi: 10.3389/fimmu.2026.1730342

Figure Lengend Snippet: CD39 inhibition combined with IL-2cx reshapes the immune landscape of the tumor microenvironment. WT mice were injected s.c. with B16F10-OVA cells and treated with PBS (gray), POM-1 (red), IL-2/anti-IL-2 complex (IL-2cx, green), or the combination POM-1 + IL-2cx (blue). (A) Frequencies of T-I NK cells (left) and KLRG-1 + NK cells (right). (B) Frequencies of GzmA + , Perforin + , or CD107a + T-I NK cells. (C) Frequencies of T-I CD4 + conventional T cells (Tconv left) and Treg (right). (D) Frequencies of CD39 + cells within T-I Tconv cells. (E) Frequencies of GzmB + CD39 + Tconv cells. (F) Frequencies of T-I monocytic myeloid-derived suppressor cells (M-MDSC). (G) Frequencies of T-I CD39 + , CD38 + , or CD73 + expressing M-MDSCs. All data were collected on day 15 p.i. Data are presented as mean ± SD. Statistical analysis was performed using one-way ANOVA with multiple comparisons. Non-significant differences are not shown; * P ≤ 0.05; ** P ≤ 0.01; *** P ≤ 0.001; **** P ≤ 0.0001.

Article Snippet: The CD39 inhibitor POM-1 (TOCRIS) was injected i.p. in 200 μL PBS containing 250 μg of POM-1 on days 5, 7, 10, and 13 p.i.

Techniques: Inhibition, Injection, Derivative Assay, Expressing